| Scott D Dreiker, MD | |
|
8 Commerce Blvd, Suite 301, Middleboro, MA 02346-1030 | |
| (774) 213-0380 | |
| (774) 213-0389 |
| Full Name | Scott D Dreiker |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 33 Years |
| Location | 8 Commerce Blvd, Middleboro, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811998727 | NPI | - | NPPES |
| 3140229 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 76530 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Steward Medical Group Inc | 2860688728 | 1404 |
News Archive
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
"While two new members of House Appropriation Committee's State and Foreign Operations Subcommittee profiled in the Center for Global Health Policy's "Science Speaks" blog yesterday voted first for and then against the President's Emergency Plan For AIDS Relief, one of the three profiled in the blog on Thursday is an unambiguous supporter of global health initiatives, having played a pivotal role in virtually all legislation guiding America's HIV response for more than a decade," "Science Speaks" reports.
Among today's health policy headlines, a new Politico poll highlights the deep divide in public opinion that exists regarding the repeal of the health law.
GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
› Verified 9 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
"While two new members of House Appropriation Committee's State and Foreign Operations Subcommittee profiled in the Center for Global Health Policy's "Science Speaks" blog yesterday voted first for and then against the President's Emergency Plan For AIDS Relief, one of the three profiled in the blog on Thursday is an unambiguous supporter of global health initiatives, having played a pivotal role in virtually all legislation guiding America's HIV response for more than a decade," "Science Speaks" reports.
Among today's health policy headlines, a new Politico poll highlights the deep divide in public opinion that exists regarding the repeal of the health law.
GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
› Verified 9 days ago
| Entity Name | Steward Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
"While two new members of House Appropriation Committee's State and Foreign Operations Subcommittee profiled in the Center for Global Health Policy's "Science Speaks" blog yesterday voted first for and then against the President's Emergency Plan For AIDS Relief, one of the three profiled in the blog on Thursday is an unambiguous supporter of global health initiatives, having played a pivotal role in virtually all legislation guiding America's HIV response for more than a decade," "Science Speaks" reports.
Among today's health policy headlines, a new Politico poll highlights the deep divide in public opinion that exists regarding the repeal of the health law.
GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott D Dreiker, MD 8 Commerce Blvd, Suite 301, Middleboro, MA 02346-1030 Ph: (774) 213-0380 | Scott D Dreiker, MD 8 Commerce Blvd, Suite 301, Middleboro, MA 02346-1030 Ph: (774) 213-0380 |
News Archive
AVEO Pharmaceuticals, Inc. today announced that the United States Adopted Names (USAN) Council, in consultation with the World Health Organization (WHO) International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "ficlatuzumab" (pronounced fye" kla tue' zue mab) for AV-299, a potent, functional anti-HGF/c-MET antibody internally discovered at AVEO.
"While two new members of House Appropriation Committee's State and Foreign Operations Subcommittee profiled in the Center for Global Health Policy's "Science Speaks" blog yesterday voted first for and then against the President's Emergency Plan For AIDS Relief, one of the three profiled in the blog on Thursday is an unambiguous supporter of global health initiatives, having played a pivotal role in virtually all legislation guiding America's HIV response for more than a decade," "Science Speaks" reports.
Among today's health policy headlines, a new Politico poll highlights the deep divide in public opinion that exists regarding the repeal of the health law.
GlaxoSmithKline and Genelabs Technologies, Inc announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1.30 per share in cash. This strategic acquisition will strengthen GSK's effort to develop and deliver novel therapies against the hepatitis C virus (HCV).
› Verified 9 days ago
Julia F Edelman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 511 W Grove St, Suite 304, Middleboro, MA 02346 Phone: 508-947-0800 Fax: 508-947-8133 |